Dapagliflozin, Gliclazide

Dapagliflozin and Gliclazide is a combination medication used for the treatment of type 2 diabetes. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which works by reducing the reabsorption of glucose in the kidneys, leading to increased urinary glucose excretion and lower blood sugar levels. Gliclazide, on the other hand, is a sulfonylurea that stimulates the release of insulin from the pancreas, helping to lower blood sugar levels.
This medication is typically prescribed for patients who have not achieved adequate blood sugar control with lifestyle modifications or other oral diabetes medications. Dapagliflozin and Gliclazide should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
Some common side effects of Dapagliflozin and Gliclazide include hypoglycemia (low blood sugar), weight loss, increased urination, and urinary tract infections. Patients should monitor their blood sugar levels regularly and seek medical attention if they experience symptoms of low blood sugar, such as dizziness, sweating, or confusion.